A detailed history of Goldman Sachs Group Inc transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Goldman Sachs Group Inc holds 317,460 shares of PDSB stock, worth $1.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
317,460
Previous 90,474 250.89%
Holding current value
$1.03 Million
Previous $358,000 159.78%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.55 - $4.02 $578,814 - $912,483
226,986 Added 250.89%
317,460 $930,000
Q1 2024

May 15, 2024

BUY
$3.85 - $6.59 $300,253 - $513,940
77,988 Added 624.6%
90,474 $358,000
Q4 2023

Feb 13, 2024

SELL
$3.95 - $6.58 $3,302 - $5,500
-836 Reduced 6.28%
12,486 $62,000
Q3 2023

May 14, 2024

BUY
$4.8 - $6.4 $4,012 - $5,350
836 Added 6.7%
13,322 $67,000
Q3 2023

Nov 14, 2023

SELL
$4.8 - $6.4 $69,004 - $92,006
-14,376 Reduced 51.9%
13,322 $67,000
Q2 2023

May 14, 2024

SELL
$5.03 - $9.9 $289,089 - $568,982
-57,473 Reduced 67.48%
27,698 $139,000
Q2 2023

Aug 14, 2023

SELL
$5.03 - $9.9 $289,089 - $568,982
-57,473 Reduced 67.48%
27,698 $139,000
Q1 2023

May 14, 2024

BUY
$5.68 - $11.99 $412,850 - $871,493
72,685 Added 582.13%
85,171 $523,000
Q1 2023

May 11, 2023

BUY
$5.68 - $11.99 $483,771 - $1.02 Million
85,171 New
85,171 $523,000
Q2 2022

Aug 15, 2022

SELL
$3.05 - $6.68 $90,743 - $198,743
-29,752 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$4.78 - $8.43 $9,607 - $16,944
-2,010 Reduced 6.33%
29,752 $184,000
Q4 2021

Feb 14, 2022

BUY
$7.76 - $14.35 $158,047 - $292,266
20,367 Added 178.74%
31,762 $257,000
Q3 2021

Nov 10, 2021

BUY
$9.33 - $17.08 $106,315 - $194,626
11,395 New
11,395 $170,000

Others Institutions Holding PDSB

About PDS Biotechnology Corp


  • Ticker PDSB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,458,700
  • Market Cap $91.9M
  • Description
  • PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...
More about PDSB
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.